Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kronos Bio Inc
KRON | US
0.96
USD0.01
1.05%
KRON | US
About Kronos Bio Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.96
Open
0.92
High
0.97
Low
0.92
Kronos Bio Inc. a clinical-stage biopharmaceutical company focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742 an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors which is in phase 1/2 clinical trial; and Lanraplenib a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo California.
View LessKRON | US
Risk
50.9
Sharpe
0.02
Luna's Score
57/100
Recommendation
Hold
Luna says (KRON | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
53.4%1 month
50.9%3 months
52.0%6 months
93.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.46
Debt to equity
0.22
Debt to assets
0.17
Ent. to EBITDA
0.81
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-94.24M
MarketCap
57.88M
MarketCap(USD)
57.88M
Div. yield
-
Op. margin
-649.00
Erngs. growth
-
Rev. growth
44.20
Ret. on equity
-63.00
Short ratio
8.29
Short perc.
1.56
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.15
Range1M
0.19
Range3M
0.61
Volumes: Market Activity
Rel. volume
2.03
Price X volume
109.57K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.81 | - | Expensive |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.46 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 52.02 | - | Lower Risk |
| Debt to Equity | 0.22 | -1.23 | Expensive |
| Debt to Assets | 0.17 | 0.25 | Cheaper |
| Market Cap | 57.88M | - | Emerging |
